Escalier raises $19M series B

Escalier Biosciences B.V. (Nijmegen, Netherlands) raised $19 million on March 13 in a series B round led by Forbion. Existing investors New Science Ventures and BioGeneration Ventures also participated.

Escalier plans to begin clinical trials in mid-2018 of a topical small molecule inhibitor of RAR-related orphan receptor C thymus-specific isoform (RORgamma2; RORgammaT) to treat psoriasis. It is also developing an oral small molecule against the same target...